(Reuters) – Conatus Pharmaceuticals Inc said its experimental drug reduced the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial. The drug, emricasan, showed a statistically significant reduction in the protein fragment, caspase-cleaved cytokeratin 18 (cCK18), when compared with a placebo, in the overall patient population, according to the three-month data. Patients with advanced liver disease and cirrhosis usually have higher levels of cCK18.
Read more from the original source:
Conatus liver drug shows promise in mid-stage trial
